MONDAY, June 5, 2023 (HealthDay News) — For patients with hormone receptor-positive advanced breast cancer with disease progression during or after treatment with an aromatase inhibitor, capivasertib-fulvestrant therapy results in significantly longer progression-free survival than fulvestrant alone, according to a study published in the June 1 issue of the New England Journal of Medicine.
Nicholas C. Turner, M.D., Ph.D., from the Royal Marsden Hospital in London, and colleagues conducted a randomized trial involving premenopausal, perimenopausal, and postmenopausal women and men with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer who had a relapse or disease progression during or after aromatase inhibitor treatment, with or without previous cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor therapy. A total of 708 participants were randomly assigned to receive capivasertib plus fulvestrant or placebo plus fulvestrant in a 1:1 ratio.
People are also reading…
The researchers found that the median progression-free survival was 7.2 and 3.6 months in the capivasertib-fulvestrant group and the placebo-fulvestrant group, respectively, in the overall population (hazard ratio for progression or death, 0.60). The median progression-free survival was 7.3 and 3.1 months, respectively, in the AKT pathway-altered population (hazard ratio, 0.50). Rash and diarrhea were the most frequent adverse events of grade 3 or higher in patients receiving capivasertib-fulvestrant.
“Our findings suggest that capivasertib-fulvestrant treatment improved outcomes regardless of previous exposure to a CDK4/6 inhibitor and reinforce the evidence that single-agent endocrine therapy has poor outcomes after receipt of a CDK4/6 inhibitor,” the authors write.
The study was funded by AstraZeneca, the manufacturer of capivasertib. In addition, several authors disclosed ties to industry.
Stay connected with us on social media platform for instant update click here to join our Twitter, & Facebook
We are now on Telegram. Click here to join our channel (@TechiUpdate) and stay updated with the latest Technology headlines.
For all the latest Health News Click Here
For the latest news and updates, follow us on Google News.
Denial of responsibility! NewsAzi is an automatic aggregator around the global media. All the content are available free on Internet. We have just arranged it in one platform for educational purpose only. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials on our website, please contact us by email – [email protected]. The content will be deleted within 24 hours.
